

CNS SPECTRUMS®

The International Journal of Neuropsychiatric Medicine

ACADEMIC SUPPLEMENT

Mixed Amphetamine Salts Extended Release for the Treatment of ADHD in Adults: Current Evidence

Introduction

J. Biederman

Single- and Multiple-Dose Pharmacokinetics of an Oral Mixed Amphetamine Salts Extended-Release Formulation in Adults

S.B. Clausen, S.C. Read, S.J. Tulloch

Long-Term Safety and Effectiveness of Mixed Amphetamine Salts Extended Release in Adults With ADHD

J. Biederman, T.J. Spencer, T.E. Wilens, R.H. Weisler, S.C. Read, S.J. Tulloch

An Interim Analysis of the Quality of Life, Effectiveness, Safety, and Tolerability (Q.U.E.S.T.) Evaluation of Mixed Amphetamine Salts Extended Release in Adults With ADHD

D.W. Goodman, L. Ginsberg, R.H. Weisler, A.J. Cutler, P. Hodgkins

Long-Term Cardiovascular Effects of Mixed Amphetamine Salts Extended Release in Adults With ADHD

R.H. Weisler, J. Biederman, T.J. Spencer, T.E. Wilens

Faculty Affiliations and Disclosures

Joseph Biederman, MD, is chief of the Pediatric Psychopharmacology Research Unit at the Massachusetts General Hospital in Boston. He has been a speaker for Cephalon, Eli Lilly, McNeil, and Shire; is on the advisory boards of Cephalon, Eli Lilly, Janssen, McNeil, Novartis, and Shire; and has received research support from Abbott, Bristol-Myers Squibb, Cephalon, Eli Lilly, the Lilly Foundation, Janssen, McNeil, the National Institute of Child Health and Human Development (NICMH), the National Institute on Drug Abuse (NIDA), the National Institute of Mental Health (NIMH), Neurosearch, New River, Pfizer, Prechter Foundation, Shire, and the Stanley Medical Institute.

Susan B. Clausen, PhD, was senior director in the Clinical Research Department at Shire Pharmaceutical Development in Rockville, Maryland, and owned stock in Shire at the time of this study. She is currently vice president of clinical research at Advancis Pharmaceutical Corporation in Germantown, Maryland.

Andrew J. Cutler, MD, is affiliate assistant professor in the Department of Psychiatry and Behavioral Medicine at the University of South Florida in Tampa, and president of CORE Research, Inc in Maitland, Florida. He has been a consultant to Abbott Laboratories, AstraZeneca, Bristol-Myers Squibb, Otsuka America, Pfizer, and Shire; and has received research support from Abbott, AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Johnson & Johnson, the Lilly Foundation, Merck, Organon, Otsuka America, Pfizer, Sanofi-Synthelabo, Shire, Solvay, and Wyeth.

Lawrence D. Ginsberg, MD, is president and CEO of Red Oak Psychiatry Associates in Houston, Texas. He has been a consultant to AstraZeneca, Bristol-Myers Squibb, Celltech, Cephalon, Elan, Eli Lilly, Forest, GlaxoSmithKline, Janssen, McNeil, NIMH, Novartis, Pfizer, Sanofi-Synthelabo, Sepracor, Shire, Takeda, UCB Pharma, and Wyeth; has been a speaker for AstraZeneca, Bristol-Myers Squibb, Celltech, Cephalon, Elan, Eli Lilly, Forest, GlaxoSmithKline, Janssen, McNeil, NIMH, Novartis, Organon, Pfizer, Sanofi-Synthelabo, Shire, and Wyeth; and has received research support from Alkermes, AstraZeneca, Bristol-Myers Squibb, Celltech, Cephalon, Elan, Eli Lilly, Forest, Janssen, GlaxoSmithKline, McNeil, Neurocrine Biosciences, New River, NIMH, Novartis, Organon, Otsuka America, Pfizer, Sanofi-Synthelabo, Sepracor, Shire, Takeda, UCB Pharma, and Wyeth.

David W. Goodman, MD, is assistant professor in the Department of Psychiatry and Behavioral Sciences at Johns Hopkins University School of Medicine in Baltimore; director of Suburban Psychiatric Associates, LLC in Baltimore; and director of the Adult Attention Deficit Disorder Center of Maryland in Lutherville. He has been a consultant to Alza, Eli Lilly, Forest, GlaxoSmithKline, McNeil, and Shire; has been a speaker for Abbott, Alza, Bristol-Myers Squibb, Eli Lilly, Forest, GlaxoSmithKline, McNeil, Parke-Davis, Pfizer, Shire, and Wyeth; has received research support from Alza, Forest, GlaxoSmithKline, McNeil, and Shire; has received honoraria from Abbott, Alza, Bristol-Myers Squibb, Eli Lilly, Forest, GlaxoSmithKline, McNeil, Parke-Davis, Pfizer, Shire, and Wyeth; and owns stock in Bristol-Myers Squibb, Johnson & Johnson, and Pfizer.

Paul Hodgkins, PhD, PMP, RAC, is director of medical programs at Shire Pharmaceuticals Inc. in Wayne, Pennsylvania. He also owns stock in Shire.

Stephanie C. Read, MS, is senior medical program manager within Global Medical Affairs at Shire Pharmaceuticals Inc. in Wayne, Pennsylvania. She also owns stock in Shire.

Thomas J. Spencer, MD, is associate professor of psychiatry in the Department of Psychiatry at Harvard Medical School in Boston, Massachusetts. He has been a speaker for Eli Lilly, GlaxoSmithKline, McNeil, Novartis, Shire, and Wyeth; and is on the advisory boards of and receives research support from Eli Lilly, GlaxoSmithKline, McNeil, Novartis, Pfizer, and Shire.

Simon J. Tulloch, MD, is head of the CNS Strategic Therapeutic Area at Shire Pharmaceuticals Inc. in Wayne, Pennsylvania. He also owns stock in Shire.

Richard H. Weisler, MD, is adjunct professor of psychiatry at the University of North Carolina at Chapel Hill and adjunct assistant professor of psychiatry at Duke University in Durham, North Carolina. He has been a consultant to, has been a speaker for, and has received research support from Abbott, AstraZeneca, Biovail, Bristol-Myers Squibb, Cephalon, Corcept, Eli Lilly, Eisai, Forest, GlaxoSmithKline, Janssen, Johnson & Johnson, Lundbeck, MediciNova, Merck & Co, Novartis, Organon, Pfizer, Saegis, Sanofi-Synthelabo, Schwabe, Shire, Solvay, Synaptic, TAP, UCB Pharma, Vela, and Wyeth; and owns stock in Bristol-Myers Squibb, Merck & Co, and Pfizer.

Timothy E. Wilens, MD, is associate professor of psychiatry in the Department of Psychiatry at Harvard Medical School, and director of Substance Abuse Services in Pediatric Psychopharmacology at Massachusetts General Hospital in Boston. He has been a consultant to, has been a speaker for, and has received grant support from Abbott, Alza, Celltech, Eli Lilly, GlaxoSmithKline, Janssen, the NICMH, the NIDA, the NIMH, NeuroSearch, Novartis, Ortho-McNeil, Pfizer, Saegis, Sanofi-Synthelabo, and Shire.

CNS SPECTRUMS®

The International Journal of Neuropsychiatric Medicine

EDITOR

Jack M. Gorman, MD
Mount Sinai School of Medicine
New York, NY

ASSOCIATE AND FOUNDING EDITOR

Eric Hollander, MD
Mount Sinai School of Medicine
New York, NY

INTERNATIONAL EDITOR

Joseph Zohar, MD
Chaim Sheba Medical Center
Tel-Hashomer, Israel

ASSOCIATE INTERNATIONAL EDITORS

EUROPE

Donatella Marazziti, MD
University of Pisa
Pisa, Italy

MID-ATLANTIC

Dan J. Stein, MD, PhD
University of Cape Town
Cape Town, South Africa

FAR EAST

Shigeto Yamawaki, MD, PhD
Hiroshima University School
of Medicine
Hiroshima, Japan

CONTRIBUTING WRITERS

Joseph Biederman, MD
Susan B. Clausen, PhD
David W. Goodman, MD
Richard H. Weisler, MD

SUPPLEMENT EDITOR

Eric Hollander, MD

BOARD OF ADVISORS

NEUROLOGISTS

Mitchell F. Brin, MD
University of California, Irvine
Irvine, CA

Jeffrey L. Cummings, MD
University of California, Los Angeles
Los Angeles, CA

Jerome Engel, Jr., MD, PhD
University of California, Los Angeles
Los Angeles, CA

Mark S. George, MD
Medical University of South Carolina
Charleston, SC

Deborah Hirtz, MD
National Institute of Neurological
Disorders and Stroke, NIH
Rockville, MD

Richard B. Lipton, MD
Albert Einstein College of Medicine
Bronx, NY

C. Warren Olanow, MD, FRCPC
Mount Sinai School of Medicine
New York, NY

Steven George Pavlakis, MD
Maimonides Medical Center
Brooklyn, NY

Stephen D. Silberstein, MD, FACP
Thomas Jefferson University
Philadelphia, PA

Michael Trimble, MD, FRCP, FRPsych
National Hospital for Neurology
and Neurosurgery
London, United Kingdom

PSYCHIATRISTS

Margaret Altemus, MD
Cornell University Medical College
New York, NY

Dennis S. Charney, MD
Mount Sinai School of Medicine
New York, NY

Dwight L. Evans, MD
University of Pennsylvania
Philadelphia, PA

Siegfried Kasper, MD
University of Vienna
Vienna, Austria

Martin B. Keller, MD
Brown Medical School
Providence, RI

Lorrin M. Koran, MD

Stanford University School of Medicine
Stanford, CA

Yves Lecrubier, MD
Hôpital de la Salpêtrière
Paris, France

Herbert Y. Meltzer, MD
Vanderbilt University Medical Center
Nashville, TN

Stuart A. Montgomery, MD
St. Mary's Hospital Medical School
London, United Kingdom

Charles B. Nemeroff, MD, PhD
Emory University School of Medicine
Atlanta, GA

Humberto Nicolini, MD, PhD
National Mexican Institute of Psychiatry
Mexico City, Mexico

Stefano Pallanti, MD, PhD
University of Florence
Florence, Italy

Katharine Phillips, MD
Brown Medical School
Providence, RI

Harold A. Pincus, MD
Western Psychiatric Institute & Clinic
RAND-University of Pittsburgh Health
Institute, Pittsburgh, PA

Scott L. Rauch, MD
Massachusetts General Hospital
Charlestown, MA

Alan F. Schatzberg, MD
Stanford University School of Medicine
Stanford, CA

Thomas E. Schlaepfer, MD
University of Bonn
Bonn, Germany

Stephen M. Stahl, MD, PhD
University of California, San Diego
La Jolla, CA

Norman Sussman, MD, DFAPA
New York University Medical School
New York, NY

Karen Dineen Wagner, MD, PhD
The University of Texas Medical Branch
Galveston, Texas

Herman G.M. Westenberg, MD
University Hospital Utrecht
Utrecht, The Netherlands

Stuart C. Yudofsky, MD
Baylor College of Medicine
Houston, TX

MBL COMMUNICATIONS Corporate Staff

CEO & PUBLISHER

Darren L. Brodeur

ASSOCIATE PUBLISHER

Elizabeth Katz

MANAGING EDITOR

Christopher Naccari

SENIOR EDITOR

Deborah Hughes

NATIONAL ACCOUNT MANAGER

Kathleen J. Skae, MBA

SALES & MARKETING ASSOCIATE

Jennifer Gomez

DEPUTY SENIOR EDITOR

José R. Ralat

ACQUISITIONS EDITORS

Lisa Arrington
Shoshana Bauminger

ASSOCIATE EDITOR-ENDURING MATERIALS

Shelley Wong

ASSOCIATE EDITORS

Peter Cook
Dena Croog

INTERN

Stephanie Spano

ART DIRECTOR

Derek Oscarson

GRAPHIC DESIGNER

Brad Evans

CONTROLLER

John Spano

OFFICE MANAGER

Manuel Pavón

INFORMATION TECHNOLOGY

Clint Bagwell Consulting

CORPORATION COUNSEL

Lawrence Ross, Esq.
Bressler, Amery, and Ross

CNS SPECTRUMS®

The International Journal of Neuropsychiatric Medicine

December 2005

Volume 10 – Number 12 – Supplement 20

5 Introduction

By Joseph Biederman, MD

6 Single- and Multiple-Dose Pharmacokinetics of an Oral Mixed Amphetamine Salts Extended-Release Formulation in Adults

By Susan B. Clausen, PhD, Stephanie C. Read, MS, and Simon J. Tulloch, MD

16 Long-Term Safety and Effectiveness of Mixed Amphetamine Salts Extended Release in Adults With ADHD

By Joseph Biederman, MD, Thomas J. Spencer, MD, Timothy E. Wilens, MD, Richard H. Weisler, MD, Stephanie C. Read, MS, and Simon J. Tulloch, MD, on behalf of the SLI381.304 Study Group

26 An Interim Analysis of the Quality of Life, Effectiveness, Safety, and Tolerability (QU.E.S.T.) Evaluation of Mixed Amphetamine Salts Extended Release in Adults With ADHD

By David W. Goodman, MD, Lawrence Ginsberg, MD, Richard H. Weisler, MD, Andrew J. Cutler, MD, and Paul Hodgkins, PhD, PMP, RAC

35 Long-Term Cardiovascular Effects of Mixed Amphetamine Salts Extended Release in Adults With ADHD

By Richard H. Weisler, MD, Joseph Biederman, MD, Thomas J. Spencer, MD, and Timothy E. Wilens, MD

Founded in 1996, *CNS Spectrums* is an *Index Medicus* journal and is available on MEDLINE under the citation *CNS Spectr.* It is available online at www.cnsspectrums.com. *CNS Spectrums* is also distributed to all CINP members and is accredited for international CME by EACIC.

CNS Spectrums (ISSN 1092-8529) is published monthly by MBL Communications, Inc., 333 Hudson Street, 7th Floor, New York, NY 10013.

One-year subscription rates: domestic \$140; foreign \$195; in-training \$85. For subscriptions: Phone: 212-328-0800; Fax: 212-328-0600; Web: www.cnsspectrums.com.

Postmaster: Send address changes to *CNS Spectrums* c/o MMS, Inc, 185 Hanson Court, Suite 110, Wood Dale, IL 60191-1150.

For editorial inquiries, please fax us at 212-328-0600 or e-mail us at dh@mbllcommunications.com. For bulk reprint purchases, please contact: Christopher Naccari at cdn@mbllcommunications.com.

Opinions and views expressed by authors are their own and do not necessarily reflect the views of the publisher, MBL Communications, Inc., or the editorial advisory board. Advertisements in *CNS Spectrums* are accepted on the basis of adherence to ethical medical standards, but acceptance does not imply endorsement by *CNS Spectrums* or the publisher.

CNS Spectrums is a registered trademark of CNS Spectrums, LLC, New York, NY. Permission to reproduce articles in whole or part must be obtained in writing from the publisher.

BPA member since July 2005.



Copyright ©2005 by MBL Communications, Inc. All rights reserved. Printed in the United States.

Disclaimer

This academic supplement is sponsored by Shire Pharmaceuticals Inc. Sponsorship of this review does not imply the sponsor's agreement with the views expressed herein. Although every effort has been made to ensure that drug doses and other information are presented accurately in this publication, the ultimate responsibility rests with the prescribing physician. Neither the publisher, the sponsor, nor the authors can be held responsible for errors or for any consequences arising from the use of information contained herein. Readers are strongly urged to consult any relevant primary literature. No claims or endorsements are made for any drug or compound currently under clinical investigation. This supplement may contain information concerning a use or dosage schedule that has not been approved by the US Food and Drug Administration.